Safinamidum
compositum chemicum
Safinamidum est medicamentum pharmaceuticum et inhibitor monoaminorum oxidasis B reversibilis. Substantia in morbo Parkinson tractando et maturo et in cursibus progressivis adhibeatur[1].
 |
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
| Cognitores | |
|---|---|
| ChemSpider | 116349 |
| PubChem | 131682 |
| DrugBank | DB06654 |
| Natura chemica | |
| |
| |
| Formula summarum | C 17H 19FN 2O 2 |
| Massa molaris | 302.34 g/mol |
| Natura pharmacologica | |
| Codex ATC | N04BD03 (WHO) |
| Semivita biologica | 20-30 h |
| Excretio | renibus (75%) |
| Ad usum therapeuticum | |
| Applicatio | per os |
| MedlinePlus | a617025 (Anglice) |
Natura Safinamidi
recensereNatura chemica
recensereNomen suum est N2-{4-[(3-fluoro-benzyl)oxy]benzyl}-L-alanino-amidum. Massa molaris sua 302.34 g/mol.
Natura pharmacologica
recensereSafinamidum est MAO-B inhibitor reversibilis et medicamentum therapia morbi Parkinson et maturi et progressivi.
Notae
recensere- ↑ Caccia C., Maj R., Calabresi M., Maestroni S., Faravelli L., Curatolo L., Salvati P., Fariello R. G. (Oct 2006). "Safinamide: from molecular targets to a new anti-Parkinson drug". Neurology 67 (7 Suppl 2): S18-23
Nexus interni
Nexus externi
recensere- FDA de Safinamidi (PDF) (Anglice)